Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2854-2859

  De Placido, Sabino ^a   Carlomagno, Chiara ^a   Ciardiello, Fortunato ^a   De Laurentiis, Michelino ^a   Pepe, Stefano ^a   Ruggiero, Angela ^a   Tortora, Giampaolo ^a   Panico, Luigi ^a   D'Antonio, Antonio ^a   Pettinato, Guido ^a   Petrella, Giuseppe ^a   Bianco, A Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS;

EID: 0032740806     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 351: 1451-1467, 1998.
2. Early Breast Cancer Trialists' Collaborative Group. Polichemotherapy for early breast cancer: an overview of the randomized trials. Lancet, 352: 930-942, 1998.
3. Clark, G. M., Dressler, L. G., Owens, M. A., Pounds, G., Oldaker, T., and McGuire, W. L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N. Engl. J. Med., 320: 627-633, 1989.
4. Sigurdsson, H., Baldetorp, B., Borg, A., Dalberg, M., Ferno, M., Killander, D., and Olsson, H. Indicators of prognosis in node-negative breast cancer. N. Engl. J. Med., 522: 1045-1053, 1990.
5. Clark, G. M., and McGuire, W. L. Follow-up study of HER/neu amplification in primary breast cancer. Cancer Res., 51: 944-948, 1991.
6. Toikkanen, S., Helin, H., Isola, J., and Joensuu, H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-years follow-up. J. Clin. Oncol., 10: 1044-1048, 1992.
7. Ross, J. S., and Fletcher, J. A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. Oncologist, 3: 237-252, 1998.
8. Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L. C., and Mayall, B. H. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845-855, 1992.
9. Gasparini, G., Gullik, W. J., Bevilacqua, P., Sainsbury, J. R. C., Meli, S., Boracchi, P., Testolin, A., La Malfa, G., and Pozza, F. Human breast cancer: prognostic significance of the c-erbB2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy and conventional pathologic features. J. Clin. Oncol., 10: 686-695, 1992.
10. Fox, S. B., and Harris, A. L. The epidermal growth factor receptor in breast cancer. J. Mammary Gland Biol. Neoplasia, 2: 131-141, 1997.
11. Gasparini, G., Pozza, F., and Harris, A. L. Evaluation and usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J. Natl. Cancer Inst., 85: 1206-1219, 1993.
12. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
13. Kim, K. J., Li, B., Wine, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelia growth factor-induced angiogenesis suppress tumor growth in vivo. Nature (Lond.), 362: 841-844, 1993.
14. Hori, A., Sasada, R., Matsutani, E., Naito, K., Sakura, Y., Fujita, T., and Kozai, Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res., 51: 6180-6184, 1991.
15. Liotta, L. A., Kleinerman, J., and Saidel, G. M. Quantitative relationships of intravascular tumor cell, tumor vessels and pulmonary metastases following tumor implantation. Cancer Res., 34: 997-1004, 1974.
16. Rak, J., Filmus, J., and Kerbel, R. S. Reciprocal paracrine interaction between tumor cells and endothelial cells: the angiogenesis progression hypotesis. Eur. J. Cancer. 32A: 2438-2450, 1996.
17. Weidner, N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat., 36: 169-180, 1995.
18. Srivasta, A., Laidler, P., Davies, R. P., Horan, K., and Hughes, L. E. The prognostic significance of tumor vascularity in intermediate thickness skin melanoma: a quantitative histologic study. Am. J. Pathol., 133: 419-423, 1988.
19. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
20. Gasparini, G., Weidner, N., Maluta, S., Pozza, F., Boracchi, P., Mezzetti, M., Testolin, A., and Bevilacqua, P. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int. J. Cancer, 55: 739-744, 1993.
21. Gasparini, G., Bonoldi, E., Viale, G., Verderio, P., Boracchi, P., Panizzoni, G. A., Radaelli, U., Di Bacco, A., Guglielmi, R. B., and Bevilacqua, P. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int. J. Cancer, 69: 205-211, 1996.
22. Fontanini, G., Lucchi, M., Vignati, S., Mussi, A., Ciardiello, F., De Laurentiis, M., De Placido, S., Basolo, F., Angeletti, C. A., and Bevilacqua, G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J. Natl. Cancer Inst., 89: 881-886, 1997.
23. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., and Gasparini, G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst., 84: 1875-1887, 1992.
24. Fox, S. B., Leek, R. D., Smith, K., Hollyer, J., Greenall, M., and Harris, A. L. Tumor angiogenesis in node-negative breast carcinomas -relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res. Treat., 29: 109-116, 1994.
25. Fregene, T. A., Knanuja, P. S., Gimotty, P. A., Kellogg, C., George, J., and Pienta, K. J. The relationship of microvessel count to tumor size, estrogen receptor status, lymph node metastasis and disease free survival in patients with stage I and II breast cancer. Int. J. Oncol., 5: 1437-1445, 1994.
26. Gasparini, G., Weidner, N., Bevilacqua, P., Maluta, S., Dalla Palma, P., Caffo, O., Barbareschi, M., Boracchi, P., Marubini, E., and Pozza, F. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. Clin. Oncol., 12: 454-466, 1994.
27. Toi, M., Inada, K., Suzuki, H., and Tominaga, T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res. Treat., 36: 193-204, 1995.
28. Ogawa, Y., Chung, Y. S., Nakata, B., Takatsuka, S., Maeda, K., Sawada, T., Kato, Y., Yoshikawa, K., Sakurai, M., and Sowa, M. Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen. Br. J. Cancer, 71: 1297-1301, 1995.
29. Heimann, R., Ferguson, D., Power, C., Recant, W. M., Weichselbaum, R. R., and Hellman, S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J. Natl. Cancer Inst., 88: 1764-1769, 1996.
30. LeDoussal, V., Tubiana-Hulin, M., Friedman, S., Hacene, K., Spyratos, F., and Brunet, M. Prognostic value of histologic nuclear grade components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer (Phila.), 64: 1914-1921, 1989.
31. Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., and Bianco, A. R. c-erbB2 overexpression decreased the benefit of adjuvant tamoxifen in early breast cancer without axillary lymph node metastases. J. Clin. Oncol., 14: 2702-2708, 1996.
32. Mc Guire, W. L., De La Garza, M., Chamness, G. C. Evaluation of estrogen receptors assays in human breast cancer tissue. Cancer Res., 37: 637-639, 1977.
33. Pepe, S., Ruggiero, A., De Laurentiis, M., Normanno, N., Fiorentino, B., Perrone, F., Carlomagno, C., De Placido, S., Panico, L., Pettinato, G., Borriello, G., and Bianco, A. R. DNA-flow cytometry (ploidy and S-phase fraction) as prognostic factor in a retrospectine series of 515 primary breast cancer. Oncol. Rep., 2: 345-359, 1995.
34. Kaplan, E. L., Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
35. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem. Rep., 50: 163-170, 1966.
36. Cox, D. R. Regression models and life table. J. R. Stat. Soc., 34: 187-220, 1972.
37. Bianco, A. R., De Placido, S., Gallo, C., Pagliarulo, C., Marinelli, A., Petrella, G., D'Istria, M., and Delrio, G. Adjuvant therapy with tamoxifen in operable breast cancer: 10 year results of the Naples (GUN) study. Lancet, ii: 1095-1099, 1988.
38. Vermulen, P. B., Libura, J., Libura, M., Hellemans, P. W. J., Van Marck, E., Van Oosterom, A. T., and Dirik, L. Y. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. Correspondence. J. Natl. Cancer Inst., 87: 1797-1802, 1995.
39. Van Hoef, M. E. H. M., Knox, W. F., Dhesi, S. S., Howell, A., and Schor, A. M. Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur. J. Cancer, 29A: 1141-1145, 1993.
40. Axelsson, K., Ljung, B. M. E., Moore, D. H., Thor, A. D., Chew, K. L., Edgerton, S. M., Smith, H. S., and Mayall, B. H. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl. Cancer Inst., 87: 997-1008, 1995.
41. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
42. Boemh, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 335-336, 1997.
43. Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y. N., and Brem, H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer, 57: 920-925, 1994.